Work

PA-130 Dasatinib and Quercetin in Patients with Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy: First Report from the Safety Run-in of the Phase II DART Trial

Year: 2026

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)03498-1

Authors: Christoph Schaefers, Melinda Tan, Morie Gertz, Taxiarchis Kourelis, Rahma Warsame, Joselle Cook, Moritz Binder, Wilson I. Gonsalves, Chen Wu, De Menezes Silva Corraes Andre, Malvika Gupta, Zuoyi Shao, Kevin M. Regan, Rayaan Kamal, Amylou C. Dueck, Megan Weivoda, Nadine H. Abdallah, Yi Lin

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7213866162

Cites:

Cited by:

Related to: 10